HAYWARD, Calif. and Cambridge, UK (March 22, 2006) – Solexa, Inc. (Nasdaq: SLXA) today announced that John West, chief executive officer of Solexa, will make a presentation to the investment community at the Future Leaders in the Biotech Industry conference on Thursday, March 30, 2006, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the Millennium Broadway Hotel and Conference Center in New York City.  The Future Leaders conference will be presented by BioCentury and Thomson Financial.

Interested investors may gain access to a live audio webcast and slide presentation via the Internet by visiting the “Investors” section of the Company’s Web site at www.solexa.com.  The presentation will be archived on the Web site for 14 days.  

- ENDS - 

About Solexa

Solexa, Inc. is developing and preparing to commercialize the Solexa Genome Analysis System, which will be used to perform a range of analyses including whole genome resequencing, gene expression analysis and small RNA analysis. Solexa expects its first-generation instrument, the 1G Genome Analyzer, to generate over a billion bases of DNA sequence per run and to enable whole genome resequencing below $100,000 per sample, making it the first platform to reach this important milestone. Solexa's longer-term goal is to reduce the cost of human resequencing to a few thousand dollars for use in a wide range of applications from basic research through clinical diagnostics. For further information, please visit www.solexa.com. 

This press release contains "forward-looking" statements, including statements related to the current views of Solexa management as to future products, product development, commercialization of the Company’s novel genetic analysis technology, and the expansion and success of Solexa's commercial application of its genomics technologies.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "predicts," "expects," "envisions," "hopes," "estimates," "intends," "will," "continue," "may," "potential," "should," "confident," "could" and similar expressions are intended to identify forward-looking statements. There can be no assurance that such expectations of any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. There are a number of important factors that could cause the results of Solexa to differ materially from those indicated by these forward-looking statements including, among others, risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2004, its Form 10-Q for the quarter ended September 30, 2005 and its registration statement on Form S-3 filed with the SEC on January 27, 2006. Solexa does not undertake any obligation to update forward-looking statements. 

For more information, please contact:  

Solexa, Inc.   

Linda Rubinstein, Vice President and CFO

lrubinstein@solexa.com

(510) 670-9300  

European Media Contact:

Northbank Communications

Sue Charles, CEO

+44 (0)20 7886 8152

s.charles@northbankcommunications.com  

Investor Contacts: 

Lippert/Heilshorn & Associates

Jody Cain (jcain@lhai.com)

Mariann Ohanesian (mohanesian@lhai.com)

310/691-7100